US EditionHER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options
- On May 30, 2025, in Chicago, MEDSIR revealed positive phase II findings from the TUXEDO-3 trial assessing HER3-DXd for treating brain metastases in individuals affected by metastatic breast cancer or advanced non-small cell lung cancer.
- The trial investigated a new treatment in individuals suffering from advanced cancer complications, specifically those with ongoing brain metastases or leptomeningeal involvement originating from solid tumors, conditions that currently have limited therapeutic options.
- The study showed intracranial responses of 23.8% in metastatic breast cancer and 30% in advanced non-small cell lung cancer, with 65% survival at three months in leptomeningeal disease.
- Dr. Matthias Preusser described the study as an important step forward, highlighting that patients’ overall well-being and cognitive performance were maintained or showed improvement throughout the course of treatment.
- Results suggest HER3-DXd could offer a novel treatment for secondary central nervous system involvement, addressing unmet needs in difficult-to-treat brain metastases and leptomeningeal disease.
42 Articles
42 Articles
HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options
The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast or lung cancer and active brain metastases, and leptomeningeal disease from solid tumors.These results were…
HER3’s Rising Role in Cancer and Therapy
In recent years, the receptor tyrosine kinase HER3 (also known as ErbB3) has emerged from relative obscurity to occupy a central role in cancer biology and therapeutic development. Part of the broader HER/ErbB family, which includes EGFR (HER1), HER2, and HER4, HER3 has long been recognized for its unusual biochemical properties. Unlike its family members that possess robust intrinsic kinase activity, HER3’s kinase function is weak, almost vesti…
HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options - PressReach
The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast or lung cancer and active brain metastases, and leptomeningeal disease from solid tumors. These results were presented as an oral presentationat the American Society of Clinical Oncology (ASCO) 2025 annual meeting, with select results simultaneously published in Nature Medicine. The findings …
Coverage Details
Bias Distribution
- 81% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
